Emerging therapeutic targets and agents for glioblastoma migrating cells.
Glioblastoma multiforme (GBM) is one of the most common and most aggressive types of primary brain tumors in humans. Even with aggressive surgical resections using state of the art preoperative and intraoperative neuroim-aging, along with the most recent techniques in radiotherapy and chemotherapy, the prognosis for GBM patients remains dismal. Survival after diagnosis is about 12-14 months. The tumor cells which already have migrated into normal brain tissue beyond the surgical resection margin account for the inability to effectively treat this tumor. Understanding how to control the migration of GBM cells is paramount to future therapies. In this review, we will focus on the emerging targets and agents which are being exploited to inhibit the migration of glioma cells in GBM.
Preston Robert Tisch Brain Tumor Center, Departments of Surgery (Neurosurgery) and Neurobiology, Duke University, Durham, USA.
Chunhui
C
Di
Austin K
AK
Mattox
Steve
S
Harward
Cory
C
Adamson
D000970:Antineoplastic Agents / Q000494:pharmacology / Q000627:therapeutic use*; D001921:Brain / Q000473:pathology*; D001932:Brain Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy; D002465:Cell Movement; D003131:Combined Modality Therapy; D016207:Cytokines / Q000378:metabolism; D005260:Female; D005909:Glioblastoma / Q000188:drug therapy* / Q000473:pathology* / Q000628:therapy; D006801:Humans; D036341:Intercellular Signaling Peptides and Proteins / Q000494:pharmacology / Q000502:physiology; D008297:Male; D058990:Molecular Targeted Therapy; D014411:Neoplastic Stem Cells / Q000378:metabolism / Q000502:physiology; D011379:Prognosis; D018125:Receptors, Transforming Growth Factor beta / Q000378:metabolism; D015398:Signal Transduction
D000970:Antineoplastic Agents; D016207:Cytokines; D036341:Intercellular Signaling Peptides and Proteins; D018125:Receptors, Transforming Growth Factor beta